Vivani Medical Menandatangani Perjanjian dengan Novo Nordisk bagi Menilai NPM-139, Implan Semaglutide Miniatur dengan Tindakan Ultra Jangka Panjang bagi Pengurusan Berat Badan Kronik

Novo Nordisk will carry out an internal, non-exclusive evaluation of semaglutide implants supplied by Vivani. The announcement provides no financial terms or timelines, implying limited near-term read-through for earnings or guidance.

Analysis

Novo Nordisk will carry out an internal, non-exclusive evaluation of semaglutide implants supplied by Vivani. The announcement provides no financial terms or timelines, implying limited near-term read-through for earnings or guidance.